signature to patients with immunodeficiency will require further investigation.

Michael Hummel, Ph.D.
Harald Stein, M.D.
Charité Campus Benjamin Franklin
D-12200 Berlin, Germany
Harald.Stein@charite.de

Reiner Siebert, M.D.
Christian-Albrechts-Universität zu Kiel
25105 Kiel, Germany
for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe

Vitamins C and E and the Prevention of Preeclampsia

TO THE EDITOR: The report by Rumbold et al. on the Australian Collaborative Trial of Supplements (ACTS) and the accompanying editorial by Jeyabalan and Caritis (April 27 issue)1,2 overlooked a key reason for the lack of effect of vitamin C on the prevention of preeclampsia. Ascorbate administration is based on the hypothesis that different intakes will produce different concentrations and hence outcomes. Because plasma ascorbate concentrations were not reported, we estimated them from known data. On the basis of data from young women who were not pregnant,3 the placebo and treatment groups in the study by Rumbold et al. probably had similar plasma and tissue ascorbate concentrations. The time–concentration curve for vitamin C is sigmoidal, with plasma concentrations nearing a plateau of 70 to 80 μM at an intake of 200 mg per day.3,4 Doses of 1 g per day have little effect on plasma or intracellular ascorbate concentrations. Corrections for estimated increased ascorbate needs in pregnancy5 do not change the conclusion that the concentrations in women in the control group were near saturation.

An appropriate study would measure the effect of ascorbate supplementation in women who were shown to have low plasma ascorbate concentrations at entry. Such subjects exist: among women between the ages of 19 and 30 years in the United States, the lowest 10th percentile receive only 40 mg of vitamin C per day.5 Plasma measurements and attention to the pharmacokinetics of vitamin C are required before a conclusion can be made regarding whether supplementation has benefit.

Sebastian J. Padayatty, M.D., Ph.D.
Mark Levine, M.D.
National Institutes of Health
Bethesda, MD 20892


TO THE EDITOR: Rumbold et al. concluded that vitamin C and E supplementation in nulliparous women did not prevent preeclampsia — findings that concurred with those of our trial in high-risk women.1 Our study suggested possible harmful effects of these antioxidants in women with clinical risk factors, including an increased frequency of infants with low birth weight (the principal neonatal end point) and an increased use of medication (antihypertensive agents, corticosteroids, and magnesium sulfate). Rumbold et al. also reported an increased requirement for antihypertensive treatment. In exploratory analysis, we found an earlier onset of both preeclampsia and delivery among women who received such supplementation.

Variable definitions make comparisons between studies difficult.2 We used the definition of preeclampsia — proteinuric hypertension — adopted by the International Society for the Study of Hypertension in Pregnancy (ISSHP).3 Rumbold et al. used a less specific definition of hypertension and one or more of the following: proteinuria, renal insufficiency, liver disease, neurologic...
problems, hematologic disturbances, or fetal-growth restriction. Applying the ISSHP definition to the data of Rumbold et al. leads to an increase in the incidence of preeclampsia among women receiving antioxidants, as compared with controls (4.7% vs. 2.8%). We calculated this difference to be significant (risk ratio, 1.70; 95% confidence interval, 1.06 to 2.75; P = 0.03). To evaluate unexpected findings, a meta-analysis of trials that used similar interventions is invaluable. Further analysis must ensure that similar definitions of end points are used.

Annette L. Briley, M.Sc.
Lucilla Poston, Ph.D.
Andrew H. Shennan, M.D.
King’s College London
London SE1 7EH, United Kingdom
annette.briley@kcl.ac.uk


THE AUTHORS REPLY: Padayatty and Levine highlight the finding that plasma concentrations of vitamin C near a plateau with an intake of 200 mg per day. In our trial, we were not able to measure ascorbate concentrations because of funding limitations. On the basis of questionnaires regarding dietary intake, 13.9% of the participants in our study had a daily intake of vitamin C that was below the 70 mg or more recommended during pregnancy. At least 7.4% of women in the control group would not have reached plasma ascorbate saturation. The effects of antioxidant supplementation on the risk of the primary study outcomes were similar among women with a dietary intake of vitamin C that was below the recommended intake or more. There remains a need for further assessment of the effects of antioxidant supplementation among women with a low dietary intake of vitamin C.

Briley and colleagues present a summary of the findings of their trial of vitamin C and E supplementation in women with clinical risk factors for preeclampsia. In contrast, our trial involving nulliparous women did not find any effects of supplementation with vitamins C and E on intrauterine growth restriction (the primary end point) or other measures of infant growth.

A primary outcome for our trial was the development of preeclampsia, for which we used the definition adopted by the Australasian Society for the Study of Hypertension in Pregnancy. Although we agree that variable definitions often make comparisons difficult, there remains a lack of consensus worldwide on the definition of hypertensive disease in pregnancy. Until this issue is resolved, it is important that studies collect sufficient information to allow for a variety of definitions for an assessment of the level of disease. As Briley et al. point out, on the basis of the ISSHP definition, the incidence of preeclampsia in our study was 4.7% in the group receiving supplementation and 2.8% in the control group. However, according to our calculations, this difference is not significant (P = 0.08, with a step-down Sidak adjustment for multiple primary end points).

In our trial, supplementation with vitamins C and E during pregnancy did not reduce the risk of preeclampsia in nulliparous women.

Caroline A. Crowther, F.R.A.N.Z.C.O.G.
Alice R. Rumbold, Ph.D.
Jeffrey Robinson, F.R.A.N.Z.C.O.G.
University of Adelaide
Adelaide SA 5005, Australia
caroline.crowther@adelaide.edu.au

for the ACTS Study Group